Bristol-Myers Squibb (BMY) Tops Q1 EPS by 9c; Raises Outlook
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/13/2026
- S&P 500 notches record-high close as rate-hike worries ease
- Oil settles down 2% on weak demand outlook, hefty US crude build
- BofA lifts server CPU TAM to $210bn+ on the rise of AI agents
- Burry doubles down on Nebius short after stock surges 34% on earnings
- JPMorgan gets bullish on Salesforce, says concerns are "overblown"
- Exclusive-Silver Lake in talks to buy Workday, sources say
- Crude Inventory Rose 17.2 Million Barrels Last Week - EIA
- Citi agrees to acquire rewards platform Kard Financial
- Burry doubles down on Nebius short after stock surges 34% on earnings
- Total darkness, then sunset as full eclipse wows spectators in Spain
Bristol-Myers Squibb Co. (BMY) PT Raised to $53 at Deutsche Bank
April 27, 2018 9:19 AM EDTDeutsche Bank raised its price target on Bristol-Myers Squibb Co. (NYSE: BMY) to $53.00 (from $52.00) while maintaining a Hold rating.
... MoreBristol-Myers Squibb (BMY) Reports Clinical Trial Collaboration with Advantagene Inc.
April 27, 2018 7:16 AM EDTAdvantagene, Inc. today announced that the company entered into a clinical trial collaboration with Bristol-Myers Squibb (NYSE: BMY) to evaluate the safety, tolerability, and preliminary efficacy of Advantagenes investigational Gene Mediated Cytotoxic Immunotherapy (GMCI, aglatimagene besadenovec + valacyclovir), in combination with Bristol-Myers Squibbs programmed death-1 (PD-1) immune checkpoint inhibitor, Opdivo (nivolumab), in newly diagnosed malignant glioma patients receiving standard of care (SOC) surgery and radiation with or without temozolomide. This study is being conducted in collaboration with leading... More
